Background: Osseointegration, an approach for direct skeletal attachment of a prosthesis to an amputated limb, may address many of the problems associated with socket prostheses. The safety of osseointegration remains uncertain. The aim of this study was to summarize evidence on functional and clinical outcomes, as well as adverse effects of osseointegration for patients with a limb amputation.
Introduction
Following limb amputation, patients are usually provided with a socket-suspended prosthesis, which represents the current standard of care. However, these traditional sockets can be problematic owing to residual volume changes, poor suspension, failure in load transfer and stability, and skin problems, thereby reducing use of the prosthesis and overall quality of life 1 -5 . Over the past two decades, osseointegration has emerged as a novel approach for the attachment of an externally fitted prosthesis to an amputated limb. This approach may address many of the socket-related problems, as it involves direct attachment of the prosthesis to the residual bone. The concept of osseointegration was proposed by Swedish Professor Per-Ingvar Branemark, and its principle is based on the ability of living bone cells to attach to metal surfaces 6 . After successful experimental studies in rabbit models, osseointegration was introduced in humans in dental implants 7 , with progression to bone-anchored hearing aids and other implants 8 . Osseointegration usually involves two surgical procedures in which the metal implant is inserted into the bone of the arm or leg, and this implant penetrates through the skin. The artificial limb or prosthesis is easily attached to this implant with a connector (Figs 1 and 2) .
Osseointegration prostheses have been reported to offer many advantages compared with socket prostheses, including improved walking and joint movement, longer walking distance, increased stability, ability to put on and take off the prosthesis quickly, better comfort when sitting, and improved image and quality of life 9 -16 . There remain concerns about the risk of adverse events such as infection, osteomyelitis and other complications, as well as their management 17 . The aim of this study was to summarize the evidence on clinical and functional outcomes, as well 
Methods

Data sources and search strategy
This review was conducted in accordance with PRISMA guidelines 18 . Observational studies (prospective cohort, nested case-control, case-control, retrospective cohort), case studies, case series, qualitative studies, nonrandomized studies and RCTs were sought in MEDLINE, Embase, Web of Science, and the Cochrane Library from inception to 23 April 2018. The computer-based searches combined free and Medical Subject Heading (MeSH) search terms and combinations of keywords related to the intervention (such as 'osseointegration', 'bone regeneration') and population (for example 'amputation', 'artificial limbs'). Only articles published in English and describing studies in humans were considered. Reference lists of relevant articles were scanned manually for additional studies likely to have been missed by the electronic search. Details of the MEDLINE search strategy are provided in Appendix S1 (supporting information).
Study selection
The following studies were included: those enrolling consecutive patients with upper or lower limb amputations who were managed with an osseointegration implant system, and had follow-up reporting on clinical and functional outcomes, adverse events or complications associated with osseointegration. The intervention was any osseointegrated prosthesis, either a single-or two-stage procedure. Studies based on osseointegrated finger or digital prostheses were not included. The initial screening of titles and abstracts to retrieve potentially relevant articles was performed by one reviewer. Detailed evaluation of the full texts of these articles was undertaken independently by two reviewers to determine whether they met all inclusion criteria.
Data extraction and quality assessment
Using a standard form, the following data were extracted: study publication date, study design, geographical location, baseline mean or median age, percentage of men, type of amputation and indication for amputation, eligibility criteria for implantation, type of implantation, duration of follow-up, sample size and outcomes. The methodological quality of non-randomized studies, including cohort and case-control studies, was assessed using the nine-point Newcastle-Ottawa Scale (NOS) 19 . This uses three predefined domains, namely: selection of participants (population representativeness), comparability (adjustment for confounders) and ascertainment of outcomes of interest. A maximum of 4 points is assigned for selection, 2 points for comparability and 3 points for outcome. A total of 9 points on the NOS reflects the highest study quality. Based on previously published evidence 20, 21 , studies that received a score of 9 points were judged to be at low risk of bias, studies that scored 7 or 8 points to be at medium risk, and those that scored 6 points or fewer to be at high risk of bias.
Outcome measures and definitions
Outcomes extracted were: daily prosthetic use; implant survival rates; adverse events and complications; and measures of function, mobility, satisfaction and quality of life assessed by validated outcome measures such as the 6-min walk test (6MWT) 22 , Timed Up and Go (TUG) test 23 , K-levels 24 , Short Form 36 (SF-36 ® ; Optum, Eden Prairie, Minnesota, USA) scores 25 , Questionnaire for Persons with Transfemoral Amputation (Q-TFA) scores 26 , the Amputation Mobility Predictor (AMPPRO) 27 , life habits questionnaire (LIFE-H) 28 and the Lower Extremity Functional Scale (LEFS) 29 . The majority of these outcome measures are self-reported questionnaires. The SF-36 ® is a generic measure for the assessment of health-related quality of life. The results of this score are presented in eight subscales. The Q-TFA is a condition-specific outcome measure used for transfemoral amputees, and reflects current prosthetic use, mobility, problems and global health. Quality-of-life assessments are conducted using the SF-36 ® and the Q-TFA global score. Walking ability is evaluated using the 6MWT and the TUG test.
Data synthesis and analysis
Where possible, the rates of adverse events, such as infections (calculated as the number of patients with adverse events during follow-up as a proportion of the total number of participants), with 95 per cent confidence intervals, were estimated across studies. The Freeman-Tukey variance-stabilizing double arcsine transformation 30 was used in estimating the rates because of the binary nature of the data and low rates of some of the outcomes. Given the variety of measures reported for the outcomes and inconsistent reporting, a formal meta-analysis could not be performed; rather a narrative synthesis was conducted. The findings of such studies were summarized in tables that included the main characteristics of the study and the results in natural units as reported by the investigators. Stata ® release 14 (StataCorp, College Station, Texas, USA) was used for all statistical analyses.
Results
Study identification and selection
The initial search of relevant databases and manual scanning of reference lists of relevant studies identified 177 potentially relevant citations (Fig. 3) . After the initial screening based on titles and abstracts, 42 articles remained for full-text evaluation. Twenty articles were excluded because: they included populations or interventions not relevant to the review (7); reported outcomes that were not relevant (4); described populations based on finger prostheses (4); described a study protocol (one); or were written in German (4) . The patients in the latter studies overlapped with those in another study 31 already included in the review. The remaining 22 articles 9,11 -16,31-45 comprising 13 unique studies met the inclusion criteria and were included in the review.
Study characteristics and quality
The studies were published between 2003 and 2017 ( Table 1) . They were conducted in Europe (Sweden, the Netherlands, Austria, Germany and the UK) and Australia. Most were based on the prospective Osseointegrated Prostheses for the Rehabilitation of Amputees (OPRA) study undertaken in Sweden. A variety of study designs were employed, including observational cohort (prospective or retrospective), prospective case-control, case series or reports, and qualitative studies. Although the majority of studies had a before-and-after design, two 11, 16 compared outcomes in patients using osseointegrated prostheses with those in patients using socket prostheses. One retrospective cohort study 44 split patients into two groups to compare outcomes between the first two previous designs and the final design of the osseointegrated implant system. No RCT was identified. The methodological quality of the included observational cohort and case-control studies based on NOS criteria ranged from 4 to 8.
Baseline characteristics of study populations
The sample size of cohorts (excluding case reports or series) ranged from 11 to 100 participants ( Table 1) . Three studies 33, 40, 41 were case series or reports comprising between one and five patients. Although the study populations varied and included patients with amputations of the lower and upper limbs, most included patients with transfemoral amputations (Table S1 , supporting information). Traumatic injury and tumours were the major indications for amputation. The mean age of study participants at implantation ranged from 42 to 48 years. In a case series 33 of five patients with peripheral artery disease (PAD), age at implantation ranged from 56 to 84 years. The mean interval between amputation and implantation, and the mean duration of follow-up after implantation ranged from 9 to 19 years and 1⋅0 to 8⋅0 years respectively. Most studies used a two-stage procedure; the implant type included: the Integral Leg Prosthesis (ILP;
Orthodynamic, Lübeck, Germany) or osseointegration prosthesis, Osseointegrated Prosthetic Limb (OPL; Permedica, Milan, Italy), OPRA and the endo-exo femur prosthesis system, which is now known as the ILP 44 . To be considered for an osseointegration prosthesis, common inclusion criteria reported by all studies were problems with using a conventional socket prosthesis, adequate bone quality, suitability for surgery based on medical and physical examinations, and motivation to comply with treatment and follow-up requirements. Except for the case series of patients with PAD 33 , all studies considered PAD as an exclusion criterion for osseointegration surgery.
Functional outcomes
Walking ability
Seven studies 9,12,13,33,34,38,41 evaluated walking ability using one or two of the following measures: 6MWT, TUG, LIFE-H, LEFS and subitems of the Q-TFA mobility score (Table S2 , supporting information). The majority used the 6MWT and TUG test. All studies reported significant improvement in this domain at follow-up with use of an osseointegrated prosthesis compared with baseline or preoperative values when patients were using a socket prosthesis or were wheelchair-bound.
Prosthetic use
Prosthetic use was assessed by means of the Q-TFA prosthetic use score, and this was reported by five studies 9, [12] [13] [14] 33 . The prosthetic use score improved after insertion of an osseointegrated implant compared with preoperative values. Daily prosthetic use was reported by 89 per cent of patients at 2-year follow-up following insertion of an osseointegrated implant 12, 14 . In a case series 40 of two patients, which aimed to determine the effect of the osseointegrated implant together with a customized socket design compared with a conventional socket fitting on range of motion of the shoulder, both patients reported daily prosthesis use at 2-year follow-up. However, in a 2-year follow-up evaluation of 39 patients with transfemoral osseointegrated prostheses, increased prosthetic use was reported by 26 patients compared with baseline values, whereas 11 patients reported the same use and two reported less 13 . For studies that reported explicitly on the number of patients still using an osseointegrated prosthesis at the end of follow-up, estimates ranged from 68 to 100 per cent over a mean follow-up of 1-6 years ( Table S1 , supporting information).
Mobility
Six studies 12 -14,33,34,41 evaluated mobility using one or two of the following measures: LIFE-H, LEFS, AMPPRO score, K-levels and the Q-TFA subitem prosthetic mobility score (Table S2 , supporting information). All studies reported improved mobility after osseointegration surgery. In a case series 33 involving five patients with transtibial amputation and a history of PAD, of whom three were wheelchair-bound at baseline, all five patients were able to walk unaided 12 months after receiving an osseointegration implant. In a qualitative study 15 involving 13 patients with upper or lower limb amputation who had been using osseointegrated prostheses for 3-5 years 15 , patients reported improved function and freedom compared with when they used conventional socket prostheses.
Other functional outcomes
Hagberg and colleagues 11 evaluated hip range of motion and comfort when seated, comparing individuals with osseointegrated prostheses versus those with socket prostheses. None of the individuals with an osseointegrated prosthesis reported restriction in hip motion and only one reported discomfort when sitting. Gait patterns were compared in normal controls and patients who had previously had a sock prosthesis that was converted to an osteointegrated implant. After 2 years, patients with an implant had a significant increase in hip extension and reduction in pelvic tilt, which approached the gait patterns of the normal controls 16 . In a small series of two patients 40 , both reported improved prosthetic function and a decrease in restriction of range of motion using the implant with customized sockets compared with a conventional socket prosthesis.
Pain
Apart from one study 12 that evaluated pain using the SF-36 ® bodily pain subscore and reported significant improvement in this domain at 2 years after osseointegration compared with the preoperative situation, none of the other studies used a validated pain questionnaire. Several studies assessed pain as an adverse event or complication after osseointegration. In a case series 33 involving five patients with transtibial amputation and a history of PAD who received an osseointegration implant, four were pain-free after 1 year. In the case series 40 of two patients, no pain was reported at the stump on wearing a prosthesis after 2 years. In a prospective follow-up of 100 individuals with osseointegrated implants, severe phantom limb pain was reported as the main reason why two patients were not using their prostheses 35 . In 2-year follow-up of 51 patients with osseointegrated implants by Brånemark and colleagues 14 , five reported episodic pain during rehabilitation and three reported pain on weight-bearing, which was associated with loosening of the implants. Among 39 of 45 unilateral transfemoral amputees who were treated with an osseintegrated implant and followed for 2 years, only one patient reported not using the prosthesis at all owing to loading pain; this was associated with loosening 13 . In the same study, although the patients showed substantial improvements in prosthetic function and physical quality of life, they reported no significant change in phantom limb pain or in pain from the back, shoulders and contralateral limb. In follow-up of 16 of 18 transhumeral amputees who received osseointegrated percutaneous implants, after a median of 8 years, two patients reported pain on loading and three had phantom pain in their arm 43 . In a prospective follow-up of 86 patients with transfemoral amputation who were treated with an osseointegration implant, one patient was unable to load the residual limb because of severe pain, and this led to removal of the implant 32 .
Quality of life
Eight studies 9,12 -14,33,34,38,41 assessed general and/or condition-specific health-related quality of life using the LIFE-H, LEFS, SF-36 ® and Q-TFA global score. These outcomes at follow-up were compared with the preoperative status or when using socket prostheses. All studies reported considerable improvement in quality of life after a mean of 2 years (Table S2 , supporting information). In a qualitative study 15 of 13 patients who had been using an osseointegrated prosthesis for 3-15 years, all reported substantial improvement in functional abilities, as well as quality of life. However, participants expressed fear of sustaining fractures and developing infections that could curtail their improved function and freedom.
Infections
Fourteen articles 9,12,14,31 -36,38,39,42-44 reported on infections. Given that some of the studies were conducted in the same setting, there was a possibility of overlap and so the pooled infection rate was not estimated across the studies. The infection rate ranged from 1 (95 per cent c.i. 0 to 5) to 77 (59 to 88) per cent over a mean follow-up of 5 months to 5 years (Fig. 4) . The majority of infections were reported as low-grade soft tissue or superficial infections, which were treated effectively with oral antibiotics for a few days. A few patients required prolonged treatment or parenteral antibiotic therapy. In the study 44 that compared infection outcomes between the first two previous designs of the osseointegrated implant system (group 1) and the final design (group 2), 77 per cent of patients in group 1 needed surgical intervention for infection, compared with none in group 2. Deep infections were reported Hagberg and Brånemark 35 1 100 Jönsson et al. 39 Aschoff et al. 31 Hagberg et al. 12 Tillander et al. 36 Sullivan et al. 42 Tsikandylakis et al. 43 Al Muderis et al. 32 Van de Meent et al. 9 Atallah et al. 33 Muderis et al. 34 Al Muderis et al. 38 Brånemark et al. 14 Juhnke et al. 44 Fig. 4 Rates of infection across studies. Rates are shown with 95 per cent confidence intervals in two studies. One study 14 reported the development of deep infection in four of 51 patients, which was treated successfully in three; one had the implant removed owing to loosening. The other study 43 reported a deep implant infection in one patient 3⋅5 years after stage 1 osseointegration surgery, but this resolved after 3 months of oral antibiotics. Two studies 35, 36 reported the development of osteomyelitis in one patient each. In a long-term follow-up of 96 patients with transfemoral implants (most of whom were participants in the OPRA study), 16 (17 per cent) developed implant-associated osteomyelitis 45 .
Other adverse events and complications
Apart from infection, which accounted for the majority of adverse events, other adverse events and complications reported included: periprosthetic fracture, fractures of the implant (abutment), skin reactions, soft-tissue problems, stoma hypergranulation, implant failure and removal, loosening of the fixtures, mechanical complications of the abutment and revisional surgery ( Table S2 , supporting information). Three articles 12, 39, 42 reported one or two patients sustaining fracture of the prosthetic components or implant. Five 14, 31, 32, 34, 43 reported on periprosthetic fractures, with rates ranging from 4 to 44 per cent. The cumulative survival of the implant, reported in two articles 14, 43 , ranged from 83 to 92 per cent at 2 years. The implant removal rate ranged from 3 to 11 per cent across seven articles 13,14,31,35 -37,39 , and was attributed mainly to infections and loosening. Revision rates ranged from 0 to 54 per cent 31, 32, 34, 40, 43 .
A high complication rate and substantial number of adverse events following osseointegration surgery were reported by four articles. In a 2-year follow-up of 51 patients, Brånemark and colleagues 14 reported a total of 101 complications, with 46 patients having one or more complications. In 2-19 years of follow-up of 16 of 18 patients with transhumeral osseointegrated implants, a total of 43 adverse events were reported 43 . In a series 32 of 86 patients who underwent transfemoral osseointegration and were followed for a median of 34 months, 26 developed one or more complication. In fact, only 31 patients experienced no complications at all during follow-up. During follow-up of 50 patients with transfemoral osseointegrated prostheses, 27 experienced an adverse event 34 . The majority of adverse events and complications reported in these studies were managed effectively using simple strategies; none of the studies reported additional amputation or death as a result of the osseointegrated implant.
Patient satisfaction
All studies reported that patients were generally satisfied with the improvement in functional outcomes and quality of life after insertion of the osseointegrated implant. Of 37 patients who had an endo-exo femur prosthesis implanted, 35 reported that they would choose to have the procedure again under similar circumstances 31 . However, other studies 15, 42 reported patients' concerns with slowness of rehabilitation after osseointegration surgery, and fear of sustaining a fracture as a result of a fall, or acquiring infection at the skin-implant interface.
Radiological findings
Three studies 32, 37, 43 reported on radiological signs of bone remodelling during follow-up after osseointegration. Common radiological findings included proximal trabecular streaming or buttressing, distal and endosteal bone resorption, cancellization and cortical thinning; however, the extent and progression of these changes were inconsistent. Among 86 patients who underwent transfemoral osseointegration, follow-up radiographs showed stable osseous growth and no implant migration in all but one patient, as well as hypertrophic bone formation in the distal part of the femur in 10 per cent 32 .
Robustness of findings
Although the conclusions reported from the included studies generally suggested that osseointegrated prostheses for both upper and lower limb amputees are associated with improved function, mobility and quality of life, the findings should be interpreted with caution given some limitations in the study designs used, the low methodological quality of most studies, the lack of appropriate controls in some studies, outcomes self-reported by study participants, and selective reporting of outcomes.
Discussion
Using a systematic approach, this study assessed evidence on the functional and clinical outcomes, as well as adverse effects and complications of osseointegration prosthesis after limb amputation. All relevant studies reported substantial improvement in walking ability, prosthetic use, mobility, satisfaction and quality of life with an osseointegrated implant compared with the patient's preoperative status, or when using a conventional socket prosthesis. Generally, only a few patients reported pain as a complication, and this was usually associated with loading or weight-bearing. Osseointegration does not appear to improve phantom limb pain, or pain from the back, shoulders and contralateral limb.
Infection remains a major concern; the rate ranged from as low as 1 per cent to as high as 77 per cent across studies. Most were low-grade soft tissue or superficial infections at the skin-implant interface and were treated effectively with antibiotics. Two studies 14, 43 reported deep implant infection, the rates of which were low, and the majority were treated successfully; one study 45 reported implant-associated osteomyelitis in 17 per cent of patients after a mean of 8 years.
A few studies reported a substantial number of adverse events after osseointegration implant surgery, including: periprosthetic fractures, skin reactions, soft tissue problems, stoma hypergranulation, implant failure, loosening of the fixtures, mechanical complications of the abutment, and revisional surgery. Aseptic loosening, implant removal and implant fractures are rare, and many of the reported complications resolved without surgery or using simple measures. The radiological changes after osseointegration 32, 43 may suggest a predisposition to periprosthetic fracture; however, the clinical relevance remains uncertain given the absence of long-term follow-up. No study reported further amputation or death as a complication of osseointegration.
The consistent findings reported by the included studies suggest that osseointegrative implantation increases prosthetic use, and improves mobility, range of motion, gait, comfort and quality of life. The findings are relevant as they bring together the current evidence and demonstrate the potential advantages of osseointegration for amputees, and offer encouragement for continued development.
Despite the potential benefits, osseointegration is not indicated for all amputees. It is usually reserved for patients with amputations who cannot tolerate or have problems using a conventional socket prosthesis, and patients with the motivation and emotional stability to comply with rehabilitation, treatment and follow-up requirements such as stomal wound care. The whole process following osseointegration is a lifelong and challenging one. Hitherto, amputation owing to vascular disease has been regarded as a contraindication to osseointegration surgery 9, 14, 32 . However, in a case series 33 of five transtibial amputees with PAD, osseointegration improved mobility, walking ability and quality of life, as well as reducing the prevalence of pain. Given the small number of study participants and short follow-up, further evidence is required to confirm whether osseointegrated implantation will be an acceptable treatment for amputees with PAD. This patient group, of course, is the largest population of amputees, so has the greatest potential to gain from the technology. Although this review did not evaluate cost implications of osseointegration surgery for the patient and the healthcare system because of the limited evidence, it appears that the total costs associated with osseointegrated prostheses are similar to those for socket prostheses 46 . Overall, osseointegration may be a suitable, and potentially cost-effective, alternative to traditional socket prostheses in some patient populations. Further research should focus on minimizing complications of osseointegrated surgery, particularly infections, and determining which populations will benefit most from this surgery.
Several strengths and limitations of this review deserve consideration. This study systematically examined the clinical outcomes, safety issues and adverse effects associated with osseointegrated implantation currently available in the literature. The review was limited by the potential for biases in the study designs employed. However, all studies were included because of the limited evidence on the topic. A meta-analysis of the results could not be performed because of the heterogeneous nature of the studies. Nor could the results be pooled because of the overlapping studies.
On the basis of the available evidence, osseointegration limb prostheses improve prosthetic use, give better comfort when sitting, and improve walking ability, mobility, gait and quality of life. Aseptic loosening, implant removal and implant fractures are rare. Implantation of osseointegrated prosthesis is associated with an increased risk of infections, most of which are of low grade and respond to antibiotics. There is sufficient evidence of benefit from the technology to warrant its development and refinement in robust trials with validated outcome measures.
